RxDoctor Payments Data

Ahlim Alsanani, MD

Nephrology · Huntington, WVNPI 1902215908

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $302 of the $361 with a category attached, or 83.8%. 7 manufacturers reported payments, led by Amgen at 22.2% of the total. That places this record below the midpoint for nephrology clinicians in WV, where the typical reported total is $740.

$361in general payments, 2019–2025

Across 19 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$80
  • AstraZeneca$72
  • Travere Therapeutics, Inc.$71
  • Ardelyx, Inc.$43
  • Calliditas Therapeutics US Inc.$36
  • OPKO Pharmaceuticals, LLC$34
  • plus $24 from 1 others

What the payments were for

  • Food & beverage$30284%
  • Education$5916%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$361 in reported general payments places this provider in the 35th percentile of 55 nephrology providers in West Virginia.

See all nephrology providers in West Virginia

Medicare billing

Part B allowed, 2024
$105,536
Medicare patients
403
Services billed
1,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$37,687
FarxigaDapagliflozin Propanediol13$18,630
Potassium Citrate ErPotassium Citrate21$2,006
Losartan Potassium80$838
Nifedipine ErNifedipine12$563
Spironolactone22$484
Hydrochlorothiazide74$327
Calcitriol12$312
Carvedilol28$307
Potassium Chloride22$289
Labetalol Hcl13$220
Allopurinol38$219
Tamsulosin Hcl24$201
Amlodipine Besylate49$196
Atorvastatin Calcium15$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$72$18,63013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 55 nephrology providers in West Virginia.

Other nephrology in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →